WO2023018342A1 - Go-2-me and rgo 2-me hybrids, the method of obtaining them, and their application - Google Patents

Go-2-me and rgo 2-me hybrids, the method of obtaining them, and their application Download PDF

Info

Publication number
WO2023018342A1
WO2023018342A1 PCT/PL2022/050050 PL2022050050W WO2023018342A1 WO 2023018342 A1 WO2023018342 A1 WO 2023018342A1 PL 2022050050 W PL2022050050 W PL 2022050050W WO 2023018342 A1 WO2023018342 A1 WO 2023018342A1
Authority
WO
WIPO (PCT)
Prior art keywords
rgo
hybrids
obtaining
application
graphene oxide
Prior art date
Application number
PCT/PL2022/050050
Other languages
French (fr)
Inventor
Magdalena GORSKA-PONIKOWSKA
Ludwika Lipinska
Joanna GIERALTOWSKA
Magdalena Baran
Adrian CHLANDA
Krystian Kowiorski
Lucyna KONIECZNA
Mariusz BELKA
Anna KAMM
Alicja KUBAN-JANKOWSKA
Jacek GULCZYNSKI
Ewa IZYCKA-SWIESZEWSKA
Narcyz KNAP
Aleksander ZOLNIERSKI
Tomasz BACZEK
Original Assignee
Gdanski Uniwersytet Medyczny
Siec Badawcza Lukasiewicz - Instytut Mikroelektroniki I Fotoniki
Instytut Nauk Ekonomicznych Pan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gdanski Uniwersytet Medyczny, Siec Badawcza Lukasiewicz - Instytut Mikroelektroniki I Fotoniki, Instytut Nauk Ekonomicznych Pan filed Critical Gdanski Uniwersytet Medyczny
Priority to EP22856321.9A priority Critical patent/EP4384222A1/en
Publication of WO2023018342A1 publication Critical patent/WO2023018342A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Ceramic Engineering (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns the GO-2-ME or rGO-2-ME hybrids which represent stable bonding of 2-methoxyestradiol (2-ME) molecules with graphene oxide GO or reduced graphene oxide rGO, the method of obtaining them, and their application as an anti-cancer drug.
PCT/PL2022/050050 2021-08-13 2022-08-12 Go-2-me and rgo 2-me hybrids, the method of obtaining them, and their application WO2023018342A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22856321.9A EP4384222A1 (en) 2021-08-13 2022-08-12 Go-2-me and rgo 2-me hybrids, the method of obtaining them, and their application

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLP.438737 2021-08-13
PL438737A PL243445B1 (en) 2021-08-13 2021-08-13 GO-2-ME and rGO 2-ME hybrids, method of their preparation and application

Publications (1)

Publication Number Publication Date
WO2023018342A1 true WO2023018342A1 (en) 2023-02-16

Family

ID=85200946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2022/050050 WO2023018342A1 (en) 2021-08-13 2022-08-12 Go-2-me and rgo 2-me hybrids, the method of obtaining them, and their application

Country Status (3)

Country Link
EP (1) EP4384222A1 (en)
PL (1) PL243445B1 (en)
WO (1) WO2023018342A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2532449A (en) * 2014-11-19 2016-05-25 Univ Manchester Use of Nanomaterials in treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2532449A (en) * 2014-11-19 2016-05-25 Univ Manchester Use of Nanomaterials in treating cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NEWMAN SIMON P., FOSTER PAUL A., STENGEL CHLOE, DAY JOANNA M., HO YAIK T., JUDDE JEAN-GABRIEL, LASSALLE MYRIAM, PREVOST GREGOIRE, : "STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, no. 2, 15 January 2008 (2008-01-15), US, pages 597 - 606, XP093035850, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1717 *
TING ZHOU ET AL.: "Controlled release of doxorubicin from graphene oxide based charge-reversal nanocarrier", BIOMATERIALS, vol. 35, no. 13, April 2014 (2014-04-01), pages 4185 - 94, XP028668191, DOI: 10.1016/j. biomaterials . 2014.01.04 4 *
X.C. QIN ET AL.: "Folic acid-conjugated graphene oxide for cancer targeted chemophotothermal therapy", J PHOTOCHEM PHOTOBIOL B, vol. 120, 5 March 2013 (2013-03-05), pages 156 - 62, XP028524919, DOI: 10.1016/j.jphotobiol. 2012.12.00 5 *
YAO LV ET AL.: "Targeted delivery and controlled release of doxorubicin into cancer cells using a multifunctional graphene oxide", MATER SCI ENG C MATER BIOL APPL, vol. 59, February 2016 (2016-02-01), pages 652 - 660, XP029329685, DOI: 10.1016/j.msec. 2015.10.06 5 *

Also Published As

Publication number Publication date
PL243445B1 (en) 2023-08-28
EP4384222A1 (en) 2024-06-19
PL438737A1 (en) 2023-02-20

Similar Documents

Publication Publication Date Title
MX2021009259A (en) Il-2 conjugates and methods of use thereof.
CY1120373T1 (en) COMPOSITIONS CONTAINING BACTERIAL STRENGTH
WO2018229236A3 (en) Compositions comprising bacterial strains
CA3156451A1 (en) Antibodies having specificity for nectin-4 and uses thereof
MX2020007148A (en) Formulations.
WO2018234793A3 (en) Antibodies
EP4219532A3 (en) Compositions and methods for transient gene therapy with enhanced stability
BR112017008976A2 (en) Composition, viscosity increasing methods of aqueous compositions, material treatment, dextran production and enzymatic reaction.
MX2023009205A (en) Antibody drug conjugates (adcs) having enzymatically cleavable groups.
CL2021001466A1 (en) Achromosomal dynamic active systems.
PH12017501371A1 (en) Pressure-sensitive adhesives for transdermal drug delivery
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
AU2018348359A8 (en) Extended release pharmaceutical formulation and methods of treatment
PH12019502548A1 (en) Pyrazole magl inhibitors
EP4273165A3 (en) Interferon beta antibodies and uses thereof
EP4328241A3 (en) Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
WO2018174668A3 (en) Insulin analog complex with reduced affinity for insulin receptor and use thereof
WO2019139176A8 (en) Genus nicotiana f1 hybrid and use of same
EP4384222A1 (en) Go-2-me and rgo 2-me hybrids, the method of obtaining them, and their application
CR20220322A (en) Anti-pd-l1 antibody formulations
MX2023008333A (en) Nanomaterials.
WO2022090801A3 (en) Pvrl2 and/or pvrig as biomarkers for treatment
MX2021010451A (en) Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof.
WO2020115083A3 (en) Amphipols
WO2018220249A3 (en) In vitro method for diagnosing asthma or subforms thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22856321

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022856321

Country of ref document: EP

Effective date: 20240313